iRadimed IRMD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 76.7%-0.2pp | 76.9%+0.4pp | 76.5%-0.9pp | 77.4%+0.8pp | |
| Operating margin | 31.2%+1.2pp | 30%-0.6pp | 30.6%+1.2pp | 29.3%+5.8pp | |
| Net margin | 26.8%+0.6pp | 26.3%0.0pp | 26.2%+2.2pp | 24.1%+1.8pp | |
| EBITDA margin | 32.6%+1.5pp | 31.1%-0.6pp | 31.7%— | —— | |
| Free cash flow margin | 20.5%-3.6pp | 24.1%+14.9pp | 9.2%-8.1pp | 17.3%-8.5pp | |
| Returns | |||||
| Return on equity | 24.8%+0.5pp | 24.3%+0.6pp | 23.7%+6.1pp | 17.6%+3.6pp | |
| Return on assets | 21.7%+1.5pp | 20.2%+0.8pp | 19.4%+4.1pp | 15.2%+3.1pp | |
| Efficiency | |||||
| Asset turnover | 0.8×0.0× | 0.8×0.0× | 0.7×+0.1× | 0.6×+0.1× | |
| Inventory turnover | 1.7×+0.3× | 1.5×-0.2× | 1.7×-0.8× | 2.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 8×-0.9× | 8.8×+4.2× | 4.7×-4.4× | 9.1×-2.1× | |
| Quick ratio | 6.8×-0.8× | 7.6×+3.7× | 3.9×-4.6× | 8.4×-2.1× | |
| Cash ratio | 5×-1.1× | 6.1×+3.1× | 3×-3.7× | 6.8×-2.3× | |
| Per Share | |||||
| Book value per share | $7.36+8.4% | $6.79+21.0% | $5.61-3.7% | $5.83+1.7% | |
| Valuation | |||||
| Market capitalization | $1.21B+62.0% | $697.04M+16.4% | $599.06M+68.5% | $355.5M-37.7% | |
| Price / earnings | 51.3×+13.5× | 36.2×+1.4× | 34.8×+7.1× | 27.7×-33.4× | |
| Price / sales | 14×+4.1× | 9.5×+0.4× | 9.1×+2.5× | 6.7×-7.0× | |
| Price / book | 12.2×+4.0× | 8×-0.4× | 8.4×+3.6× | 4.8×-3.1× | |
| Free cash flow yield | 2%+0.1pp | 2.5%+1.5pp | 1%-1.6pp | 2.6%+0.7pp | |
| Earnings yield | 2%-0.7pp | 2.8%-0.1pp | 2.9%-0.7pp | 3.6%+2.0pp | |
| Dividend yield | 1.3%+0.2pp | 2%— | —— | —— | |
| PEG ratio | 2.6×-1.0× | 3.1×+2.0× | 1×+0.3× | 0.7×+0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are iRadimed's profit margins?
- iRadimed (IRMD) runs a 76.8% gross margin and a 32.4% operating margin, with a 27.4% net margin.
- Where do iRadimed's ratios come from?
- Every ratio is computed from iRadimed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
